(Vall d'Hebron Institute of Oncology) Researchers at the Vall d'Hebron Institute of Oncology in Barcelona show that the p95HER2-T cell bispecific antibody (TCB) can successfully guide immune cells, known as lymphocytes, directly to cancerous ones for their targeted killing. This direct delivery is achieved thanks to the p95HER2 protein, which is only located in tumor cells.
